{
    "name": "metipranolol ophthalmic",
    "comment": "Discontinued",
    "other_names": [
        "OptiPranolol (DSC)"
    ],
    "classes": [
        "Antiglaucoma",
        "Beta-Blockers"
    ],
    "source": "https://reference.medscape.com/drug/optipranolol-metipranolol-ophthalmic-343602",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: Excretion in breast milk unknown; use caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excretion in breast milk unknown; use caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Asthma, uncompensated CHF, severe COPD, symptomatic sinus bradycardia, 2nd or 3rd degree AV block, cardiogenic shock"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Caution in diabetes (may mask signs of hypoglycemia)",
                "Caution on inadequate cardiac function, latent cardiac insufficiency, cerebrovascular insufficiency, sick sinus syndrome, peripheral vascular disease, history of psychiatric illness, heart failure, diminished pulmonary function, nonallergic bronchospasm, diabetes mellitus, myasthenia gravis",
                "Patients receiving topical levobunolol & a systemic ß-adrenergic blocking agent concomitantly should be observed carefully for potential additive effects on IOP &/or systemic effects of ß-adrenergic blockade",
                "May mask signs of hyperthyroidism (ie, tachycardia)",
                "Remove contact lens prior to administration"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "metipranolol ophthalmic increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "metipranolol ophthalmic increases effects of fingolimod by pharmacodynamic synergism. Use Caution/Monitor. Both medications decrease heart rate. Monitor patients on concomitant therapy, particularly in the first 6 hours after fingolimod is initiated or after a treatment interruption of at least two weeks,  for bradycardia and atrioventricular block. To identify underlying risk factors of bradycardia and AV block, obtain a new or recent ECG in patients using beta-blockers prior to starting fingolimod."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acebutolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atenolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "betaxolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carvedilol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celiprolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "metipranolol ophthalmic increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esmolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "labetalol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nadolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nebivolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "metipranolol ophthalmic increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penbutolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pindolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "propranolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sotalol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "timolol",
            "description": {
                "common": "metipranolol ophthalmic increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "verapamil",
            "description": {
                "common": "metipranolol ophthalmic increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Burning sensation in eye",
            "percent": "3"
        },
        {
            "name": "Blepharitis",
            "percent": null
        },
        {
            "name": "Blurred vision",
            "percent": null
        },
        {
            "name": "Light intolerance",
            "percent": null
        },
        {
            "name": "Uveitis",
            "percent": null
        },
        {
            "name": "Tearing",
            "percent": null
        },
        {
            "name": "Eyelid dermatitis",
            "percent": null
        },
        {
            "name": "Browache",
            "percent": null
        },
        {
            "name": "Similar to systemic beta",
            "percent": null
        },
        {
            "name": "blockers including bradycardia",
            "percent": null
        },
        {
            "name": "aggravation of CHF",
            "percent": null
        },
        {
            "name": "nausea",
            "percent": null
        },
        {
            "name": "asthma",
            "percent": null
        },
        {
            "name": "nightmares",
            "percent": null
        },
        {
            "name": "impotence",
            "percent": null
        },
        {
            "name": "tiredness",
            "percent": null
        },
        {
            "name": "cough",
            "percent": null
        },
        {
            "name": "dyspnea",
            "percent": null
        },
        {
            "name": "epistaxis",
            "percent": null
        },
        {
            "name": "rhinitis",
            "percent": null
        },
        {
            "name": "myalgia",
            "percent": null
        },
        {
            "name": "arthritis",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "Reduction of systemic side effects by putting finger in corner of eye",
            "percent": null
        },
        {
            "name": "occluding punctum",
            "percent": null
        },
        {
            "name": "or by gentle eyelid closure",
            "percent": null
        },
        {
            "name": "without opening",
            "percent": null
        },
        {
            "name": "closing lid",
            "percent": null
        },
        {
            "name": "for",
            "percent": null
        },
        {
            "name": "min",
            "percent": null
        }
    ]
}